Biotechnology
Libevitug Approved in China as First-in-Class Treatment for Hepatitis D
BEIJING, Jan. 27, 2026 /PRNewswire/ -- Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated cirrhosis. Libevitug...
2026-01-27 16:18
4185
Moyom Biotechnology Announces Strategic Partnership with WPP Group to Elevate Aphranel's "Poetics of Time" Brand Positioning
SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- Moyom Biotechnology today announced a strategic partnership with WPP Group, a leading creative transformation company that provides integrated brand, media, public relations, data, and technology solutions worldwide. Headquartered in London, WPP Group oper...
2026-01-26 22:48
7634
BIOSeedin Winter Innovation Partnering Summit：J.P.Morgan Spotlight
SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- To enable Chinese innovative pharmaceutical companies to more efficiently connect with international resources, bioSeedin, a platform facilitating cooperation in innovative drug assets, hosted the BIOSeedin Winter Innovation Partnering Summit inSan Fra...
2026-01-26 22:00
4859
Jin Medical International Ltd. To Host Management Fireside Chat
CHANGZHOU, China, Jan. 26, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment inChina, announced today that its Chief Executive Officer, tog...
2026-01-26 21:57
17964
Divamics Showcases Lead Autoimmune Program DVI-001 and Unveils New Metabolic Program DVI-004 at JPM Week 2026
SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- Divamics (DIVAMICS), an AI-driven biotechnology company specializing in high-precision molecular discovery, highlighted the significant advancement of its internal pipeline during the Biotech Showcase™ at JPM Week 2026. The company provided updated mil...
2026-01-26 20:00
2614
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline
SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Developm...
2026-01-26 15:00
6146
Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor
* Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves the way for ISM8969 clinical study inthe United States. The Phase I clinical trial aims to evaluate safety, tolerability, and pharmacokinetics profiles. * ISM8969 is a novel oral therapeutic candi...
2026-01-23 21:30
12272
Study demonstrates effectiveness and economic value of Myriad™ in trauma and acute care surgery.
AUCKLAND, New Zealand, Jan. 21, 2026 /PRNewswire/ -- Aroa Biosurgery Limited is pleased to announce that the latest publication from its ongoing prospective study, theMyriad Augmented Soft Tissue Reconstruction Registry (MASTRR), has been published in theJournal of Trauma and Injury. MASTRR is t...
2026-01-23 03:13
4340
Mabwell Announces First-Patient Dosed in Clinical Trial of Novel CDH17-Targeting ADC 7MW4911 in the U.S.
SHANGHAI, Jan. 22, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed ina clinical trial in the U.S. of its independently developed novel CDH17-targeting antibody-drug co...
2026-01-22 22:00
6811
SK bioscience, MSD, and Hilleman Laboratories Advance Zaire ebolavirus Vaccine Development with CEPI Funding
* CEPI to provide up to USD 30 million to support development of MSD's Zaire ebolavirus vaccine * Collaboration addresses manufacturing complexity and cold-chain challenges to improve yield and thermostability * Partnership aims to expand affordable and sustainable vaccine access in low- an...
2026-01-22 21:00
6102
PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million; First Patient Dosed in Phase 1 Trial of PT0511, a Pan-KRAS Degrader
BURLINGTON, Mass., Jan. 22, 2026 /PRNewswire/ -- PAQ Therapeutics, a clinical-stage oncology company developing novel targeted protein degradation therapies for KRAS-driven cancers, today announced the closing of a Series B extension, bringing the company's total Series B financing to$77 million,...
2026-01-22 20:00
4402
Samsung Biologics reports fourth quarter and fiscal year 2025 financial results
* Recorded Q4'25 revenue of KRW 1,286 billion and FY'25 revenue of KRW 4,557 billion * Maintained momentum through consistent operational performance and robust client demand * Strengthened foundation for long-term growth through expanded manufacturing readiness and operational scale INC...
2026-01-21 15:20
5161
Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment
* Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive license and co-development collaboration to advance ISM8969 worldwide. Under the agreement, both parties hold 50% worldwide rights, and Insi...
2026-01-21 08:15
5954
Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughput Kinase Inhibitor Screening
HOUSTON, Jan. 20, 2026 /PRNewswire/ -- Sino Biological, Inc. is proud to
announce the launch of its innovativeSwiftFluo® TR-FRET Kinase Assay Kits
2026-01-20 23:00
4500
LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders
BEIJING, Jan. 20, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics f...
2026-01-20 20:00
6555
GENEIII Sets the Global Benchmark for Ergothioneine with Pharmaceutical-Grade Purity and Human Clinical Validation
SINGAPORE, Jan. 20, 2026 /PRNewswire/ -- On January 9th, GENEIII reaffirmed its global leadership in ergothioneine production and scientific validation at the "Research Without Borders • Tracing the Source with GENEIII" Global Evidence-Based Journey. GENEIII joined forces with core partners to v...
2026-01-20 18:09
4156
Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology
DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK. Under the terms of the agreement, Tesaro will acquire world-wide rights to use ALT-B4, Alteog...
2026-01-20 15:55
4857
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to iRegene's NouvNeu001, Making It the World's First iPSC Therapy with Both FTD and RMAT Recognitions
Designation underscores potential of chemically induced, off-the-shelf cell therapy to address high unmet need in Parkinson's disease, following compelling Phase I clinical data CHENGDU, China, Jan. 19, 2026 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company"), a biotechno...
2026-01-19 21:00
3386
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owne...
2026-01-19 08:02
8419
WuXi AppTec Receives Double "A" Rating from CDP for Climate Change and Water Security Leadership
SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced that it has been recognized on the "A List" for leadership in corporate transparency and performance across both Climate Cha...
2026-01-19 08:00
3587
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 321 media titles]
2026-02-16 10:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 277 media titles]
2026-02-17 19:12
Appier Delivers Record Results Driven by Agentic AI Innovation
[Picked up by 263 media titles]
2026-02-13 17:03Philips Evnia x SEGA: Elevating Immersion for YAKUZA KIWAMI 3 & DARK TIES | Unveiling the 27M2N6501L QD-OLED Monitor - Where Speed Meets Spectacle
[Picked up by 260 media titles]
2026-02-12 15:58
Most Read
Datasea Reports Second Fiscal Quarter 2026 Results
2026-02-12 22:20
8324
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
7498
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
2026-02-12 21:56
7065
